Literature DB >> 8618691

Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma.

S J Bird1, M J Brown, M E Shy, S S Scherer.   

Abstract

We report three patients who developed chronic inflammatory demyelinating polyneuropathy (CIDP) in association with malignant melanoma. In two cases, melanoma was discovered during the initial evaluation for neuropathy. Two patients also had vitiligo, an antibody-mediated disorder that may complicate melanoma. Melanoma cells and Schwann cells are both of neuroectodermal cell origin, with shared surface antigens. Shared immunoreactivity may account for the association between melanoma and CIDP, as with vitiligo.

Entities:  

Mesh:

Year:  1996        PMID: 8618691     DOI: 10.1212/wnl.46.3.822

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Immunological mechanisms in paraneoplastic peripheral neuropathy.

Authors:  J C Antoine
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

2.  Chronic inflammatory polyneuropathy revealing malignant melanoma.

Authors:  A Rousseau; F Salachas; M Baccard; J Y Delattre; M Sanson
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

3.  Chronic idiopathic demyelinating polyneuropathy (CIDP) associated with Kaposi's sarcoma.

Authors:  Yahya Celik; Nilda Turgut; Burhan Turgut; Gülsüm E Pamuk; Muzaffer Demir
Journal:  J Neurooncol       Date:  2006-06-23       Impact factor: 4.130

Review 4.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

5.  Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies.

Authors:  J C Antoine; J F Mosnier; L Absi; P Convers; J Honnorat; D Michel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

6.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

7.  Chronic inflammatory demyelinating polyneuropathy associated with metastatic malignant melanoma of unknown primary origin.

Authors:  José-Alberto Palma; Salvador Martín-Algarra
Journal:  J Neurooncol       Date:  2009-03-06       Impact factor: 4.130

8.  Limbic encephalitis following immunotherapy against metastatic malignant melanoma.

Authors:  Sharfaraz Salam; Timothy Lavin; Ayse Turan
Journal:  BMJ Case Rep       Date:  2016-03-23

9.  Paraneoplastic neuromyelitis optica spectrum disorder associated with malignant melanoma: A case report.

Authors:  Toshiki Morimoto; Shotaro Hayashida; Kei Yamasaki; Yosuke Sasahara; Tsutomu Takaki; Kazuhiro Yatera
Journal:  Thorac Cancer       Date:  2021-05-05       Impact factor: 3.500

Review 10.  Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.

Authors:  Richard J Bright; Jenny Wilkinson; Brendon J Coventry
Journal:  BMC Neurol       Date:  2014-02-07       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.